問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (非在職)

Division of General Surgery

Division of Hematology & Oncology

Taoyuan Chang Gung Memorial Hospital of The C.G.M.F. (在職)

Division of General Surgery

更新時間：2023-09-19

陳訓徹Chen, Shin-Cheh
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

  • chensc@cgmh.org.tw

Recruiting Trial

56Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳訓徹

List

110Cases

2023-12-15 - 2028-11-13

Phase III

An Interventional, Open-Label, Randomized, Multicenter, Phase 3 Study of PF-07220060 Plus Fulvestrant Compared to Investigator’s Choice of Therapy in Participants Over 18 Years of Age with Hormone Receptor-Positive, HER2-Negative Advanced/Metastatic Breast Cancer Whose Disease Progressed After Prior CDK4/6 Inhibitor-based Therapy

  • Condition/Disease

    Advanced or Metastatic Breast Cancer

  • Test Drug

    PF-07220060 Fulvestrant Everolimus Exemestane

Participate Sites
7Sites

Recruiting7Sites

2011-12-01 - 2015-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2014-05-01 - 2029-12-31

Phase III

A randomised, double-blind, parallel group, placebo-controlled multicentre Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy

  • Condition/Disease

    primary breast cancer

  • Test Drug

    Olaparib

Participate Sites
12Sites

Terminated12Sites

邱昌芳
China Medical University Hospital

Division of Hematology & Oncology

2019-01-01 - 2026-06-30

Phase III

A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)

  • Condition/Disease

    Hormone Receptor-positive, HER2-negative Early Breast Cancer

  • Test Drug

    KISQALI

Participate Sites
9Sites

Recruiting9Sites

2014-12-01 - 2021-04-28

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2014-12-01 - 2019-08-13

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2020-05-01 - 2025-06-30

Phase III

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer Following Recurrence or Progression On or After Treatment With an Aromatase Inhibitor

  • Condition/Disease

    advanced or metastatic breast cancer

  • Test Drug

    Capivasertib

Participate Sites
9Sites

Recruiting9Sites

2018-01-01 - 2022-12-31

Phase III

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Condition/Disease

    HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane

  • Test Drug

    Tesetaxel

Participate Sites
7Sites

Terminated7Sites

趙大中
Taipei Veterans General Hospital

陳訓徹
Linkou Chang Gung Medical Foundation

Division of General Surgery

2014-07-01 - 2020-03-01

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2023-06-30 - 2029-02-28

Phase III

A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH-]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy

  • Condition/Disease

    Locally Advanced or Unresectable Metastatic Breast Cancer 、Stage IV Breast Cancer

  • Test Drug

    Trodelvy

Participate Sites
10Sites

Not yet recruiting10Sites

1 6 7 8 9 10 11
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB